Personalis (NASDAQ:PSNL – Free Report) had its price objective decreased by HC Wainwright from $10.00 to $7.50 in a research report report published on Wednesday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Personalis’ Q3 2023 earnings at ($0.53) EPS, Q4 2023 earnings at ($0.51) EPS, FY2023 earnings at ($2.15) EPS, Q1 2024 earnings at ($0.42) EPS, Q2 2024 earnings at ($0.43) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.45) EPS, FY2024 earnings at ($1.74) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($0.91) EPS and FY2027 earnings at ($0.12) EPS.
Personalis Stock Up 4.6 %
Shares of NASDAQ PSNL opened at $2.05 on Wednesday. The firm has a market cap of $99.47 million, a price-to-earnings ratio of -0.87 and a beta of 1.46. Personalis has a 52-week low of $1.73 and a 52-week high of $5.58. The business’s 50 day moving average is $2.10 and its two-hundred day moving average is $2.46.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently added to or reduced their stakes in PSNL. Renaissance Technologies LLC raised its stake in Personalis by 1.1% during the second quarter. Renaissance Technologies LLC now owns 452,200 shares of the company’s stock worth $850,000 after purchasing an additional 5,000 shares during the period. Dimensional Fund Advisors LP grew its holdings in Personalis by 53.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 328,493 shares of the company’s stock worth $618,000 after acquiring an additional 114,352 shares in the last quarter. Envestnet Asset Management Inc. acquired a new position in Personalis during the 2nd quarter worth $25,000. LPL Financial LLC boosted its holdings in shares of Personalis by 9.4% in the 2nd quarter. LPL Financial LLC now owns 200,581 shares of the company’s stock valued at $377,000 after buying an additional 17,189 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Personalis by 6.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,083,685 shares of the company’s stock valued at $2,037,000 after buying an additional 64,972 shares during the period. 57.90% of the stock is currently owned by institutional investors and hedge funds.
Personalis Company Profile
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities.
See Also
- Five stocks we like better than Personalis
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- MarketBeat Week in Review – 8/7 – 8/11
- What Are Defense Contractor Stocks? How to Invest in Defense
- 3 Retailers To Watch Closely Next Week
- What is the S&P/TSX Index?
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.
